Drug Trial Radar · NCT02292654
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
Last checked: Nov 20, 2026Latest source record: Mar 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
May 1, 2015
Primary completion
Dec 9, 2019
Study completion Dec 9, 2019
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the safety and tolerability of olipudase alfa administered intravenously in pediatric participants every 2 weeks for 64 weeks. Secondary Objective: To characterize the pharmacokinetic profile and evaluate the pharmacodynamics and exploratory efficacy of olipudase alfa administered intravenously in pediatric participants every 2 weeks for 64 weeks.
Conditions
- Sphingomyelin Lipidosis
Interventions
Olipudase alfaDrug
Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From Baseline up to End of study (64 weeks)
- Number of Participants With Infusion-Associated Reactions (IARs)Time frame: Within up to 24 hours after start of any infusion (during the treatment period i.e. from Baseline up to 64 weeks)
- Number of Participants With Change in Physical ExaminationTime frame: Baseline, Week 52 (last complete assessment)
- Number of Participants With Change in Neurological ExaminationTime frame: Baseline, Week 52 (last assessment)
- Number of Participants With Abnormal Liver Function Laboratory Values at the End of StudyTime frame: At End of Study (Week 64)
- Number of Participants With Potentially Clinically Significant Vital Sign AbnormalitiesTime frame: From Baseline up to End of Study (64 weeks)
- Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) AbnormalitiesTime frame: From Baseline up to End of Study (64 weeks)
- Change From Baseline in Safety Biomarker Level: High Sensitivity C Reactive Protein (hsCRP) at Week 64Time frame: Baseline, Week 64 (pre-infusion)
- Change From Baseline in Safety Biomarker: Ceramide Level at Week 64Time frame: Baseline, Week 64 (pre-infusion)
- Change From Baseline in Safety Biomarker: Iron at Week 64Time frame: Baseline, Week 64 (pre-infusion)
- Change From Baseline in Safety Biomarker: Cardiac Troponin I and Ferritin at Week 64Time frame: Baseline, Week 64 (pre-infusion)
- Change From Baseline in Safety Biomarker: Interleukin (IL)-6 and IL-8 at Week 24Time frame: Baseline, Week 24 (pre-infusion, last assessment)
- Change From Baseline in Safety Biomarker: Calcitonin at Week 64Time frame: Baseline, Week 64 (pre-infusion)
- Doppler Echocardiogram: Absolute Change From Baseline in Left Ventricular Ejection Fraction at Week 52Time frame: Baseline, Week 52 (last assessment)
- Number of Participants With Treatment-Emergent Antibody: Treatment-Induced/Treatment-Boosted Anti-drug Antibodies and Neutralizing Antibody (NAb)Time frame: From Baseline up to Week 64
- Number of Participants With Abnormalities in Liver Ultrasound Doppler at Week 52Time frame: Week 52 (last assessment)
Locations
6 sites in 6 countries. Site status is shown where the registry gives one.
Investigational Site Number 840001
New York, New York
Investigational Site Number 076001
Porto Alegre, Brazil
Investigational Site Number 250002
Bron, France
Investigational Site Number 276001
Mainz, Germany
Investigational Site Number 380001
Udine, Italy
Investigational Site Number 826001
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.